Thailand Anti-Aging & Longevity Clinics 2027 Market Intelligence

Operator playbooks

Bumrungrad VitalLife Wellness Center (SET:BH flagship): the listed Bumrungrad Hospital Public Company has positioned VitalLife as the flagship longevity wing since the 2024 to 2025 rebrand. The 3 to 5 day Executive Longevity Assessment lists at USD 12,000 to 18,000 inclusive of full-genome and biological-age panel, NAD+ IV protocol, peptide cycle, HBOT block, physician oversight and a return-home protocol report. The 2026 expansion adds therapeutic plasma exchange and exosome adjuncts; pricing for the premium tier reaches USD 22,000. Channel power is the moat: Bumrungrad already captures roughly 32 percent of premium Hong Kong, Singapore and Middle East inbound medical-tourism volumes. The 2027 angle is converting the existing aesthetic and executive-screening patient base into a longevity-medicine repeat cohort with 1.4 to 1.8 visits per year.

BDMS Bangkok Hospital Longevity Center and Samitivej Longevity Wing (SET:BDMS group): the largest listed Thai hospital group bundles its longevity offering across Bangkok Hospital, Samitivej Sukhumvit and Samitivej Thonburi sites. Bangkok Hospital Longevity Center integrates with the Vital Life Center brand and the Bangkok MII AI clinical decision-support platform, with packages at USD 9,500 to 16,000. Samitivej Sukhumvit Longevity Wing prices at USD 8,000 to 14,000, targeting the mid-premium segment. BDMS's strategic advantage is the multi-hospital cluster effect: a patient can begin diagnostics at one site, transfer to another for therapeutic plasma exchange, and convene a multidisciplinary case review across the group. The 2027 angle is the formal BDMS Longevity Center brand consolidation across all flagship sites.

BNH Wellness Center (private-company mid-market anchor): BNH Hospital pivoted its anti-aging wing to longevity-medicine packages in 2025, with ozone therapy, NAD+ IV, HBOT and biological-age testing bundled at USD 6,000 to 11,000. BNH's positioning is mid-market: it does not compete with Bumrungrad or BDMS on the premium tier, but it captures Western digital nomads, Hong Kong and Singapore second-visit patients (after an initial Bumrungrad or BDMS programme) and Thai domestic HNW. The 2027 angle is establishing BNH as the consolidator for Bangkok mid-tier longevity volumes, with a possible regional expansion to Chiang Mai.

Banyan Tree Wellbeing Sanctuary, Aman Puri and Six Senses (Phuket Wellness Resort cluster): the Phuket cluster runs a parallel premium track. Banyan Tree Wellbeing Sanctuary 14-day longevity retreat lists at USD 38,000 to 58,000 inclusive of accommodation, full diagnostic panel, IV protocols, sleep and movement coaching, nutrition design and a 90-day return-home protocol. Aman Puri Wellness Immersion runs USD 35,000 to 65,000 over 7 to 14 days with on-site clinical staff and Bangkok hospital co-certification. Six Senses Yao Noi and Samui programmes price at USD 28,000 to 52,000. The retreat-resort cohort runs higher gross margin (room-night ADR USD 1,200 to 3,500 absorbs the basket) but is capacity-constrained because clinical components require visiting Bangkok hospital physicians or onsite-licensed Thai medical staff. The 2027 angle is whether resort retreats co-certify their own compounding pharmacy on-site (likely Banyan Tree first) or remain dependent on Bumrungrad and BDMS clinical-staff rotation.

Brikha Thailand Clinics, Bangkok Anti-Aging Center and Thonburi Jin Wellness (mid-tier and listed-specialist tail): Brikha runs a multi-site Bangkok and Chiang Mai boutique chain at USD 4,500 to 9,500 per programme, anchoring the Thai HNW domestic cohort. Bangkok Anti-Aging Center is an independent Sukhumvit specialist focused on peptide cycles and biological-age panels at USD 3,500 to 7,500. Thonburi Healthcare Group (SET:THG) runs Jin Wellness as a listed-vehicle entry into the segment. Collectively this tier captures roughly 10 to 14 percent of credentialed 2027 segment revenue and is the most exposed to Thai FDA framework compliance friction (smaller operators carry the highest compounding-pharmacy registration cost relative to revenue).

Independent boutique long tail (Bangkok, Phuket, Chiang Mai, Pattaya): the long tail of single-clinic, family-run, owner-operator boutique longevity clinics captures roughly 22 percent of 2027 segment value at sub-USD 4,000 single-modality entry tier. The Thai FDA Q1 2027 framework will compress this segment by raising the regulatory compliance baseline: clinics that cannot route through a registered compounding pharmacy will lose access to inbound buyers who need return-home protocol documentation. The 2027 angle is consolidation: BNH, Brikha and Thonburi Jin Wellness are the credible roll-up acquirers for boutique clinics with strong local referral books but inadequate compliance infrastructure.

Cultural mainstreaming and buyer-journey integration: the Brian Johnson Blueprint protocol, David Sinclair Tribe and Andrew Huberman Lab have moved longevity from niche academic to recognised consumer-health category by 2025 to 2026, with English-language search volume for biological-age testing, NAD+ IV and rapamycin off-label up 4 to 7x against 2023 baseline. Thai operators are integrating Genomics Thailand cohort substrate into their pharmacogenomic reports, replacing US and European reference cohorts with Thai-population-specific reports. Bumrungrad MII AI captures the clinical decision-support layer. The buyer journey now runs: Western podcast or social-feed exposure, Thai operator brand awareness via Instagram and TikTok, pre-arrival diagnostic-panel scheduling, on-arrival clinical assessment and protocol design, 3 to 14 day programme, return-home protocol follow-up. Repeat-purchase windows of 4 to 8 months are typical for clinic-package buyers, 9 to 14 months for resort-retreat buyers.

Unit economics: ASP per visit, COGS, ARPU, repeat rate

Hospital-owned longevity clinic packages run at USD 8,000 to 22,000 per 3 to 5 day visit, with median USD 12,500. The COGS stack: full-genome and biological-age panel (USD 1,800 to 2,800 component cost), NAD+ IV protocol (USD 1,200 to 2,200), peptide cycle (USD 800 to 1,500), HBOT block (USD 1,000 to 1,800), accommodation USD 900 to 2,200, physician oversight USD 1,500 to 3,000. Operator gross margin runs 38 to 48 percent at median visit price and steps to 50 to 58 percent at the premium tier (USD 18,000 and above) where stem-cell, exosome and therapeutic plasma exchange adjuncts carry high mark-ups. Customer acquisition cost runs USD 350 to 1,100 depending on channel: Bumrungrad and BDMS use existing patient bases at the low end; boutique clinics rely on Instagram, TikTok and concierge referral and run higher CAC.

Resort longevity retreat unit economics are structurally different. ASP runs USD 35,000 to 65,000 per person for a 7 to 14 day immersion. The COGS stack is dominated by room-night ADR (USD 1,200 to 3,500), bundling 14 nights of suite accommodation. Clinical components are subcontracted to visiting Bangkok hospital physicians or onsite-licensed Thai medical staff at USD 3,500 to 8,500 per programme. Diagnostic-panel COGS run USD 2,500 to 4,500. Food, beverage, spa, sleep and movement coaching run USD 4,000 to 8,000. Resort-cohort gross margin clears 55 to 68 percent because the room-night layer carries the basket. ARPU at the resort cohort is USD 36,000 to 52,000 per repeat purchase against 9 to 14 month repeat windows; the hospital cohort runs USD 14,000 to 19,000 ARPU at 4 to 8 month repeat windows.

Repeat-purchase rates run 18 to 24 percent at the hospital clinic cohort and 28 to 35 percent at the resort retreat cohort. The differential is buyer-journey-driven: resort-retreat buyers integrate the longevity programme into a holiday context that compounds with sleep, movement and metabolic narrative beyond pure clinical longevity. Hong Kong and Singapore buyers run highest-frequency repeat (1.4 to 1.8 visits per year), small basket. Middle East buyers run lowest repeat (0.8 to 1.1 per year), largest basket inclusive of family-member screening. Western digital nomad buyers cluster around the resort cohort and run 0.9 to 1.3 repeat. Thai domestic HNW buyers run 1.1 to 1.4 repeat at the mid-tier (Brikha, BNH, Thonburi Jin Wellness). The 2027 ARPU benchmark across the credentialed cohort lands at USD 14,500 to 19,500 with a long-tail boutique-clinic average of USD 3,500 to 6,500.